Cornea/External Disease Panel - 2023 Financial Disclosures
Francis S. Mah, MD, Co-chair
Alcon Laboratories, Aldeyra Therapeutics, Allergan, Aperta, Avellino Labs, Bausch & Lomb, Dermavent, Dompe, Evolve, EyeYon, GSK, Johnson & Johnson, KALA Pharmaceuticals, Inc., Kiora, Mallinckrodt Pharmaceuticals, Novartis, NuLids, Ocular Therapeutix, OcuTerra, Okogen, PolyActiva, Slack Publishing, Sun Pharma, Sydnexis, Tarsus, TearLab - C
Bausch & Lomb, Dompe, GSK, Sun Pharma - L
Slack Publishing - P
Sydnexis - SO
Ocular Therapeutix - S
Divya M. Varu, MD, Co-Chair
No financial relationships to disclose
Guillermo Amescua, MD
No financial relationships to disclose
Albert Y. Cheung, MD
Sight Sciences, Inc. - C
Daniel S. Choi, MD
Glaukos Corporation, Kala Pharmaceuticals - C
Vishal Jhanji, MD
No financial relationships to disclose
Amy Lin, MD
Dompe, Kala - C
Shahzad I. Mian, MD
Andover Eye Associates, Kowa American Corporation, National Eye Institute, Novartis, Vision Care - S
Michelle K. Rhee, MD
NovaBay Pharmaceuticals, The Eye Bank for Sight Restoration - C
Ocular Therapeutix - S
Elizabeth T. Viriya, MD
No financial relationships to disclose
Sumayya Ahmad, MD, Methodologist
No financial relationships to disclose
KEY:
C = Consultant/Advisor (consultant fee, paid advisory boards or fees for attending a meeting [for the past 1 year])
E = Employee (employed by a commercial entity)
L = Lecture Fees (lecture fees [honoraria], travel fees or reimbursement when speaking at the invitation of a commercial entity
O = Owner
S = Grant Support
PS = Equity/Stock Holder - Private Corporation